The panel also moderately recommends the ABCP (atezolizumab/bevacizumab/carboplatin/paclitaxel) tetragenous regimen as first-line option for patients with metastatic non-squamous NSCLC, no contraindications to immunotherapy or bevacizumab, and negative results of EGFR, ALK, ROS1, or BRAF genetic alterations, regardless of PD-L1 expression levels. This evidence concerns the gene BRAF and non-small cell lung carcinoma.